Clinical expansion Opportunity to expand the PreTRM and related biomarker tests into additional pregnancy complications such as preeclampsia, gestational diabetes, and growth restriction, positioning Sera Prognostics as a broader solution for maternal-fetal risk management.

Strategic partnerships Potential for collaboration with payer and health system networks leveraging the recent leadership hire with care management experience to improve access, reduce costs, and drive adoption of precision pregnancy care tools.

Evidence generation Strengthen sales narrative with PRIME study publications and late-breaking podium data from SMFM 2025 to demonstrate clinical and economic value to obstetricians, maternal-fetal medicine specialists, and hospital decision-makers.

Enterprise capabilities Leverage CBRE-related corporate ownership to explore enterprise-wide deployment through corporate wellness programs, patient engagement platforms, or health system subsidiaries seeking cost-effective prenatal risk assessment tools.

Market positioning Target mid to large biotech and diagnostics players with complementary portfolios (genomics, proteomics, and bioinformatics) for potential integration, co-development, or M&A conversations to scale market reach and revenue.